GlassScriptPhysician profile
Ritika Halder
NPI 1447713706
$2,289.60
in general payments reported to CMS, 2019-2025
24 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.99 · 2023: $408 · 2024: $1,275 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Education: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.64 |
| Education | $407.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $258.84 | 2023-2024 | Jakafi |
| Sanofi-Aventis U.S. LLC | $239.99 | 2024-2025 | |
| Janssen Biotech, INC. | $202.91 | 2024 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $171.86 | 2024 | Lynparza, Enhertu |
| Pfizer INC. | $162.51 | 2023-2025 | |
| Abbvie INC. | $151.61 | 2024-2025 | |
| Geron Corporation | $127.87 | 2025 | Rytelo |
| Sobi, INC | $110.82 | 2023-2024 | |
| Genentech USA, INC. | $103.53 | 2023-2024 | Phesgo, Perjeta, Alecensa |
| Karyopharm Therapeutics INC. | $101.26 | 2023 | Xpovio |
| Rigel Pharmaceuticals, INC. | $101.21 | 2024 | Rezlidhia, Tavalisse |
| Tempus Ai, INC | $99.29 | 2025 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $65.88 | 2024 | Cosela |
| Seagen INC. | $57.99 | 2023 | |
| Astellas Pharma US INC | $54.99 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $52.45 | 2024 | |
| Merck Sharp & Dohme LLC | $44.29 | 2024 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $42.91 | 2024-2025 | Vanflyta |
| Blueprint Medicines Corporation | $32.37 | 2024 | Ayvakit |
| Beigene USA, INC. | $28.90 | 2025 | Brukinsa |
| Kite Pharma, INC. | $23.98 | 2024 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.48 | 2024 | |
| Lilly USA, LLC | $16.12 | 2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $15.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritika Halder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.